Accuray Incorporated
ARAYHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Accuray Incorporated (ARAY) is listed under Medical Devices. The company carries a $15.5M market cap, placing it firmly in the micro-cap category. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Market Cap
$15.5M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-0.54
EPS (TTM)
$-0.40
EPS (Fwd)
$-0.24
ROE
-80.1%
ROA
-1.4%
Cash
$40.6M
Total Debt
$183.9M
Free CF
$10.6M
52W Change
-91.6%
Annual Financials
Cash vs Debt
Where ARAY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARAY finished 54.84% below its 150-day moving average ($0.31) and 65.00% below its 200-day moving average ($0.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARAY overbought or oversold?
At the October 20, 2026 close, ARAY's RSI(14) was 13.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ARAY has $40.6M in cash with $183.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $10.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -80.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $429.9M (2022) to $401.9M (2026).
Investors considering Accuray Incorporated should weigh the typical risks associated with ARAY's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ARAY.